Simplicity Wealth LLC Acquires New Shares in BeiGene, Ltd. (NASDAQ:BGNE)

Simplicity Wealth LLC acquired a new position in shares of BeiGene, Ltd. (NASDAQ:BGNE) in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 5,657 shares of the company’s stock, valued at approximately $885,000.

Several other large investors have also recently added to or reduced their stakes in the stock. Vanguard Personalized Indexing Management LLC grew its holdings in BeiGene by 4.8% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 1,704 shares of the company’s stock worth $306,000 after buying an additional 78 shares in the last quarter. NewEdge Wealth LLC increased its holdings in shares of BeiGene by 7.5% during the fourth quarter. NewEdge Wealth LLC now owns 1,612 shares of the company’s stock valued at $291,000 after purchasing an additional 112 shares during the period. Vestmark Advisory Solutions Inc. raised its stake in shares of BeiGene by 9.5% during the fourth quarter. Vestmark Advisory Solutions Inc. now owns 1,601 shares of the company’s stock valued at $289,000 after purchasing an additional 139 shares in the last quarter. Parkwood LLC lifted its holdings in BeiGene by 3.0% in the fourth quarter. Parkwood LLC now owns 6,464 shares of the company’s stock worth $1,166,000 after purchasing an additional 191 shares during the period. Finally, Toronto Dominion Bank lifted its holdings in BeiGene by 166.4% in the third quarter. Toronto Dominion Bank now owns 333 shares of the company’s stock worth $60,000 after purchasing an additional 208 shares during the period. 48.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently weighed in on BGNE shares. JPMorgan Chase & Co. upped their price target on shares of BeiGene from $184.00 to $186.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 19th. Bank of America cut their price objective on BeiGene from $179.30 to $164.30 and set a “neutral” rating for the company in a report on Monday, April 8th. TD Cowen lifted their target price on BeiGene from $236.00 to $254.00 and gave the stock a “buy” rating in a report on Thursday, May 9th. Sanford C. Bernstein dropped their price target on shares of BeiGene from $196.00 to $161.00 and set a “market perform” rating on the stock in a research report on Wednesday, March 27th. Finally, Guggenheim reduced their price objective on shares of BeiGene from $350.00 to $345.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, BeiGene currently has a consensus rating of “Moderate Buy” and an average target price of $251.93.

BeiGene Trading Up 0.9 %

BeiGene stock traded up $1.47 during midday trading on Monday, reaching $174.32. The stock had a trading volume of 127,705 shares, compared to its average volume of 246,886. The firm’s fifty day simple moving average is $155.56 and its two-hundred day simple moving average is $165.98. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.08 and a quick ratio of 1.84. BeiGene, Ltd. has a twelve month low of $126.97 and a twelve month high of $245.74. The firm has a market cap of $16.68 billion, a price-to-earnings ratio of -23.03 and a beta of 0.63.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($2.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.07) by $0.66. The business had revenue of $751.70 million for the quarter, compared to the consensus estimate of $670.09 million. BeiGene had a negative return on equity of 21.70% and a negative net margin of 28.39%. BeiGene’s revenue for the quarter was up 67.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($3.34) earnings per share. Equities analysts anticipate that BeiGene, Ltd. will post -8.2 EPS for the current fiscal year.

Insider Buying and Selling at BeiGene

In related news, CFO Julia Aijun Wang sold 397 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $167.08, for a total transaction of $66,330.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO John Oyler sold 26,716 shares of the stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $148.89, for a total transaction of $3,977,745.24. Following the transaction, the chief executive officer now owns 12,084 shares in the company, valued at approximately $1,799,186.76. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Julia Aijun Wang sold 397 shares of BeiGene stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $167.08, for a total transaction of $66,330.76. The disclosure for this sale can be found here. In the last quarter, insiders have sold 64,781 shares of company stock worth $10,222,381. 7.43% of the stock is currently owned by company insiders.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.